Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 double-blind randomized trial of CD101 vs caspofungin followed by oral fluconazole in candidemia
2015-005599-51Phase 2Completed
- Sponsor
- Cidara Therapeutics
- Start
- Jun 2016
- Modality
- Antimicrobial Peptides → Native Peptides → Peptides, Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of rezafungin in candidemia (2 arms), sponsored by Cidara Therapeutics. Primary endpoint: Primary efficacy endpoint. Started Jun 2016; status: completed.
02
Drugs
rezafungin
03
Conditions
candidemia
Beyond the preview
Go deeper on 2015-005599-51.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-005599-51.